Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma By Ogkologos - December 18, 2024 1068 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Strengthening EU Support for Rare Cancers under the 2028–2034 Multiannual Financial... November 17, 2025 Reflections May 26, 2021 New lung cancer treatment combo approved on NHS in England January 12, 2022 Neoadjuvant Serplulimab with S-1 Plus Oxaliplatin Followed by Adjuvant Serplulimab Significantly... June 30, 2026 Load more HOT NEWS Why Wearing Comfortable Clothes During Cancer Treatment Matters FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube,... After Lung Cancer Screening, Follow-Up Procedures May Be Riskier than Thought Patient Exposure to Anticancer Drugs Subsequently Withdrawn from the FDA Accelerated...
